CA-170

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumors or Lymphomas

Conditions

Advanced Solid Tumors or Lymphomas

Trial Timeline

May 1, 2016 → May 7, 2020

About CA-170

CA-170 is a phase 1 stage product being developed by Curis for Advanced Solid Tumors or Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT02812875. Target conditions include Advanced Solid Tumors or Lymphomas.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Solid Tumors or Lymphomas were approved

Approved (16) Terminated (1) Active (4)
ApatinibTabletsJiangsu Hengrui MedicineApproved
letrozoleJiangsu Hengrui MedicineApproved
FulvestrantAstraZenecaApproved
Zoladex and CasodexAstraZenecaApproved
GefitinibAstraZenecaApproved
Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02812875Phase 1Completed

Competing Products

20 competing products in Advanced Solid Tumors or Lymphomas

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21